COVID-19 : (Record no. 26636)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 09793nam a22004573i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6549241 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724115049.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2021 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789811498640 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9789811498633 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6549241 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6549241 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1246579055 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RA644.C67 C685 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 614.592414 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kumar, Anoop. |
| 245 10 - TITLE STATEMENT | |
| Title | COVID-19 : |
| Remainder of title | Current Challenges and Future Perspectives. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Singapore : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2021. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (212 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Introduction -- Anoop Kumar* -- INTRODUCTION -- STRUCTURE -- TYPES -- Animal Coronaviruses -- Human Coronaviruses -- GLOBAL IMPACT -- DIAGNOSIS -- TREATMENT -- PREVENTION -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- History and Epidemiology of COVID-19 -- Ruchika Sharma* -- INTRODUCTION -- CLASSIFICATION -- EMERGENCE AND SPREADING OF CORONAVIRUSES (TIMELINE) -- EPIDEMIOLOGY -- CORONAVIRUS CASES IN INDIA -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Pathogenesis of COVID-19 -- Saipriyanka Bhimaneni1, Akanksha Verma2 and Anoop Kumar2,* -- INTRODUCTION -- PATHOGENESIS -- Life Cycle of a Virus -- Entry and Replication of the Virus Inside the Host -- Coronavirus Altered Signalling Pathways -- EXTRA-PULMONARY MECHANISM -- CLINICAL MANIFESTATIONS -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Diagnosis, Treatment and Management of COVID-19 -- Vipin Bhati1, Sheetal Yadav2 and Anoop Kumar3,* -- INTRODUCTION -- DIAGNOSTIC APPROACHES -- Physical Symptoms -- Laboratory Tests: Sample Intake Methods, Analysis -- Molecular Tests (Antigen) -- Serology -- Hematological Examination -- IMAGING -- Chest X-ray Examination -- Chest Computed Tomography -- Lung Ultrasound -- FELUDA Paper Strip Test -- Treatment, Management and Prevention -- Asymptomatic and Non-serious Cases -- Mild to Moderate Cases -- Serious Cases -- Preventive Measures Public -- POST COVID-19 INFECTION TREATMENT -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Convalescent Plasma for Treatment of COVID-19 Infection. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Rahul Shukla*, Reddy Gayathri Aparnasai and Mayank Handa -- INTRODUCTION -- TREATMENT OPTIONS EXPLORED TILL DATE -- Historical Background of Passive Antibody Therapy -- Toxin Neutralization -- CONVALESCENT PLASMA-BASED THERAPEUTICS AGAINST COVID-19 -- Challenges -- Ethical Constraint -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Effect of Early Lockdown in India During the Outbreak of COVID-19: A Comparative Study of USA, Italy and India -- Gagandeep Maan, Navyashree V. Gowda, Anoop Kumar and Awanish Mishra* -- INTRODUCTION -- PROGRESSION OF THE DISEASE -- SIGNIFICANCE OF LOCKDOWN -- IMPACT OF DIAGNOSIS -- DEMOGRAPHIC DISTRIBUTION -- CONCLUSION AND FUTURE PERSPECTIVES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 Altered Immune Signalling Pathways -- Shashikanta Sau and Anoop Kumar* -- INTRODUCTION -- COVID-19 ALTERED INNATE IMMUNE RESPONSE SIGNALLING PATHWAYS -- Effects on Macrophages -- Effects on TLR Signalling Pathways -- MyD88 Dependent Signalling -- MyD88 Independent Signalling -- COVID-19 Altered the Connection Between the Innate and Adaptive Immune System -- COVID-19 Altered Humoral Response Pathways -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- COVID-19 Altered Brain Signalling Pathways -- Urvashi Langeh1, Tania Bajaj2, Priyanka Bajaj3, Swati Kaushal1, Diksha Saluja1, Shelly Agarwal1, Neelam Sharma1, Bharti Verma1, Meena Yadav1, Rima Singh1, Charan Singh2 and Arti Singh1,* -- INTRODUCTION -- NEUROPATHOLOGY OF COVID-19 -- Direct Pathway -- a. Blood Circulation Pathway -- b. Neuronal Pathway -- Hypoxic Brain Injury -- IMMUNE SYSTEM -- ANGIOTENSIN-CONVERTING ENZYME-2 (ACE-2) -- VARIOUS NEUROLOGICAL DISORDER REPORTED TO BE ASSOCIATED WITH COVID-19 -- Cerebrovascular Complications. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Encephalopathy -- Viral Encephalitis -- ROLE OF BRAIN SIGNALLING PATHWAYS IN MANIFESTATION OF COVID-19 -- Interferon Signalling Pathway -- Mitogen-activated Protein Kinase (MAPK) Pathway -- JAK/STAT Pathway -- ACE-2/ANG-(1-7)/MAS Signalling Pathway -- Unfolded Protein Response (UPR) and Autophagy Pathways -- MAJOR COMPONENTS OF NERVOUS SYSTEM INVOLVED IN COVID-19 -- Neurons -- Movement Disorders in the World of COVID-19 -- Nervous System Involvement after Infection with COVID-19 -- Multidisciplinary Research Priorities for the COVID-19 Pandemic: A Call for Action for Mental Health Science -- Lack of Dyspnea in COVID-19 Patients -- Neuroinfection May Potentially Contribute to the Pathophysiology and Clinical Manifestations of COVID-19 -- Neurological Manifestations in COVID-19 Caused by SARS-CoV-2 -- ACE- 2 -- Organ-Protective Effect of ACE- 2 and its Effect on the Prognosis of COVID-19 -- COVID-19 and ACE Inhibitors and Angiotensin Receptor Blockers (ARBs) -- Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19 -- Mitochondria of Brain Cells -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Risk Factors and Complications Associated with COVID-19 -- Gagandeep Maan and Awanish Mishra* -- INTRODUCTION -- POSSIBLE RISK FACTORS FOR SUSCEPTIBILITY OF COVID-19 -- Age -- Gender and Sex -- Medical Conditions -- Hypertension -- Diabetes Mellitus -- Cardiovascular Disorders -- Pregnancy -- Lifestyle Issues -- Smoking -- Crowding -- Occupation -- COVID-19 ASSOCIATED COMPLICATIONS -- Pneumonia and Respiratory Complications/Failure -- Nephritis and Acute Renal Failure -- Myocarditis and Cardiac Failure -- Hepatic Malfunctions/Failure -- CONCLUSION AND FUTURE PERSPECTIVES -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Possible Mechanism of Deaths Due to COVID-19 -- Aakriti Garg1 and Anoop Kumar2,* -- INTRODUCTION -- DISTRIBUTION OF DEATH CASES DUE TO COVID-19 -- POSSIBLE MECHANISM OF DEATHS WITHOUT TREATMENT -- POSSIBLE MECHANISM OF DEATHS DURING TREATMENT -- Patients with Pre-existing Medical Conditions -- Patients without Any History of Pre-existing Medical Conditions -- ROLE OF CONCOMITANT MEDICATIONS AND POSSIBLE MECHANISM OF DEATHS -- MEASURES TO MINIMIZE DEATH DUE TO COVID-19 -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Possible Targets of SARS-CoV-2 -- Navyashree V. Gowda and Anoop Kumar* -- INTRODUCTION -- POTENTIAL DRUG TARGETS -- Potential SARS-CoV-2 Targets -- Blocking Critical Viral Proteins -- Potential Targets Inhibiting the Self-Assembly Process -- Potential Human Cell Targets -- Targeting of Virulence Factor -- Targeting of Host-specific Receptor or Enzymes -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Repurposing of Drugs for COVID-19 Infections -- Aakriti Garg1 and Anoop Kumar2,* -- INTRODUCTION -- REPURPOSING OF DRUGS AGAINST SARS-COV-2 -- Chloroquine and Hydroxychloroquine -- Lopinavir/Ritonavir -- Ribavirin -- Umifenovir -- ACE Inhibitors and Angiotensin Inhibitors -- Remdesivir -- Favipiravir -- Corticosteroids -- Anti-cytokines or Immunomodulatory Agents -- Rapamycin -- Ivermectin -- Camostat and Nafamostat -- CURRENT CHALLENGES AND FUTURE PERSPECTIVES -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Herbals for COVID-19 Infection -- Amit Gupta1, Vipin Bhati2 and Anoop Kumar1,* -- INTRODUCTION -- HERBALS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME (SARS) -- In-Silico Studies -- In-Vitro Studies -- In Vivo Studies -- HERBALS AGAINST MIDDLE EAST RESPIRATORY SYNDROME (MERS). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | In-Silico Studies -- In-Vitro Studies -- In-Vivo Studies -- HERBALS AGAINST COVID-19 -- In-Silico Studies -- In-Vitro Studies -- POSSIBLE ANTIVIRAL MECHANISM OF HERBALS AGAINST SARS, MERS, AND COVID-19 -- Possible Mechanism of Herbals Against SARS -- Possible Mechanism of Herbals Against MERS -- Possible Mechanism of Herbals Against COVID-19 -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Current Challenges and Future Prospects of COVID-19 -- Ruchika Sharma* -- INTRODUCTION -- FORTHCOMING CHALLENGES AGAINST COVID-19 -- CONCLUSION AND PERSPECTIVE -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | COVID-19 (Disease)-Treatment. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Kumar, Anoop |
| Title | COVID-19: Current Challenges and Future Perspectives |
| Place, publisher, and date of publication | Singapore : Bentham Science Publishers,c2021 |
| International Standard Book Number | 9789811498633 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6549241">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6549241</a> |
| Public note | Click to View |
No items available.